Overtreatment of young adults with colon cancer: More intense treatments with unmatched survival gains

JAMA Surgery

Volumn 150, Issue 5, 2015, Pages 402-409

  Kneuertz, Peter J ^a   Chang, George J ^b   Hu, Chung Yuan ^b   Rodriguez Bigas, Miguel A ^b   Eng, Cathy ^b   Vilar, Eduardo ^b   Skibber, John M ^b   Feig, Barry W ^b   Cormier, Janice N ^b   You, Y Nancy ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COLON ADENOCARCINOMA; COLON CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; SYSTEMIC THERAPY; YOUNG ADULT; ADENOCARCINOMA; ADOLESCENT; ADVERSE EFFECTS; CLINICAL TRIAL; COLONIC NEOPLASMS; EPIDEMIOLOGY; FOLLOW UP; INCIDENCE; MEDICAL ERROR; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TIME; TRENDS; UNITED STATES;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MEDICAL ERRORS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84929665528     PISSN: 21686254     EISSN: 21686262     Source Type: Journal    
DOI: 10.1001/jamasurg.2014.3572     Document Type: Article

References (43)

1. Edwards BK, Ward E, Kohler BA, et al. Annual Report to the Nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-573.
2. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241.
3. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1695-1698.
4. You YN, Xing Y, Feig BW, Chang GJ, Cormier JN. Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med. 2012;172(3):287-289.
5. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B; Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8(4):288-298.
6. Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89(2):216-224.
7. O'Connell JB, Maggard MA, Livingston EH, Yo CK. Colorectal cancer in the young. Am J Surg. 2004;187(3):343-348.
8. McMillan DC, McArdle CS. The impact of young age on cancer-specific and non-cancer-related survival after surgery for colorectal cancer: 10-year follow-up. Br J Cancer. 2009;101(4):557-560.
9. O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28(6):558-562.
10. Quah HM, Joseph R, Schrag D, et al. Young age influences treatment but not outcome of colon cancer. Ann Surg Oncol. 2007;14(10):2759-2765.
11. Beckman EN, Gathright JB, Ray JE. A potentially brighter prognosis for colon carcinoma in the third and fourth decades. Cancer. 1984;54(7):1478-1481.
12. Chagpar R, Xing Y, Chiang YJ, et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol. 2012;30(9):972-979.
13. You YN, Dozois EJ, Boardman LA, Aakre J, Huebner M, Larson DW. Young-onset rectal cancer: presentation, pattern of care and long-term oncologic outcomes compared to a matched older-onset cohort. Ann Surg Oncol. 2011;18(9):2469-2476.
14. Abrams TA, Brightly R, Mao J, et al. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. J Clin Oncol. 2011;29(24):3255-3262.
15. Blanke CD, Bot BM, Thomas DM, et al. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol. 2011;29(20):2781-2786.
16. Hubbard J, Thomas DM, Yothers G, et al. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol. 2012;30(19):2334-2339.
17. American College of Surgeons Commission on Cancer Facility Oncology Registry Data Standards (FORDS) manual. https://www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals/fordsmanual. Accessed February 18, 2015.
18. Williams RT, Stewart AK, Winchester DP. Monitoring the delivery of cancer care: Commission on Cancer and National Cancer Data Base. Surg Oncol Clin N Am. 2012;21(3):377-388, vii.
19. André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351.
20. O'Connell MJ. Current status of adjuvant therapy for colorectal cancer. Oncology (Williston Park). 2004;18(6):751-755.
21. National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: colon and rectum cancer. http://seer.cancer.gov/statfacts/html/colorect.html. Accessed February 9, 2015.
22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
23. American College of Surgeons. Charlson/Deyo score. http://ncdbpufbeta.facs.org/?q=content/charlsondeyo-comorbidity-index. Accessed February 9, 2015.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
25. Greene FL, Page DL, Fleming ID, et al; for the American Joint Committee on Cancer. Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
26. National Comprehensive Cancer Network. NCCN guidelines: colon/rectal cancer. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed February 9, 2015.
27. American College of Surgeons. Commission on Cancer accreditation categories. https://www.facs.org/quality-programs/cancer/accredited/about/categories. Accessed February 9, 2015.
28. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-121.
29. Hoel DG, Ron E, Carter R, Mabuchi K. Influence of death certificate errors on cancer mortality trends. J Natl Cancer Inst. 1993;85(13):1063-1068.
30. Hu CY, Xing Y, Cormier JN, Chang GJ. Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. Cancer. 2013;119(10):1900-1907.
31. American Cancer Society. Cancer facts & figures 2013. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013. Accessed February 12, 2015.
32. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23(1):51-64.
33. Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M. Are we undertreating rectal cancer in the elderly? an epidemiologic study. Ann Surg. 2007;246(2):215-221.
34. Braun MS, Seymour MT. Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol. 2011;3(1):43-52.
35. Kidwell KM, Yothers G, Ganz PA, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer. 2012;118(22):5614-5622.
36. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007;25(16):2205-2211.
37. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109-3116.
38. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219-3226.
39. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609-618.
40. Goel A, Nagasaka T, Spiegel J, Meyer R, Lichliter WE, Boland CR. Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. Clin Gastroenterol Hepatol. 2010;8(11):966-971.
41. Limburg PJ, Harmsen WS, Chen HH, et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol. 2011;9(6):497-502.
42. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer: the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153-162.
43. Berg M, Danielsen SA, Ahlquist T, et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One. 2010;5(11):e13978. doi:10.1371/journal.pone.0013978.